Bicycle Therapeutics PLC
BCYC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001761612
In the last 90 days, Bicycle Therapeutics PLC insiders filed 0 open-market purchases and 5 sales; 103 institutions reported holding it in 13F filings for Q2 2026, worth $157.9M in total; no superinvestor holds it.
13F holders, Q2 2024
Institutional positions in Bicycle Therapeutics PLC as of Jun 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 107
- +12 vs. Q1 2024
- Shares held
- 39.7M
- +9.23M (+30.3%) vs. Q1 2024
- Total value
- $804.0M
- +$44.8M (+5.9%) vs. Q1 2024
- New holders
- 26
- 35 more added
- Sold out
- 14
- 25 more reduced
Compare with Q1 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting BCYC on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 103 | $157.9M |
| Q1 2026 | 98 | $173.6M |
| Q4 2025 | 109 | $276.9M |
| Q3 2025 | 99 | $285.6M |
| Q2 2025 | 110 | $286.3M |
| Q1 2025 | 95 | $354.4M |
| Q4 2024 | 97 | $586.5M |
| Q3 2024 | 105 | $915.3M |
| Q2 2024 | 107 | $804.0M |
| Q1 2024 | 95 | $759.1M |
| Q4 2023 | 101 | $567.4M |
| Q3 2023 | 101 | $651.3M |
| Q2 2023 | 85 | $618.5M |
| Q1 2023 | 89 | $498.9M |
| Q4 2022 | 87 | $695.9M |
| Q3 2022 | 79 | $538.0M |
| Q2 2022 | 82 | $381.1M |
| Q1 2022 | 105 | $884.5M |
| Q4 2021 | 101 | $1.31B |
| Q3 2021 | 69 | $591.1M |
| Q2 2021 | 54 | $376.9M |
| Q1 2021 | 39 | $341.2M |
Institutions, Q2 2024
Shares, value and share of portfolio for each institution holding Bicycle Therapeutics PLC; share changes are against Q1 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Tybourne Capital Management (HK) Ltd | 1,509,713 | $30.6M | 6.21% | −35,313−2.3% | Reduced |
| Westfield Capital Management Co LP | 1,523,856 | $30.8M | 0.15% | +484,939+46.7% | Added |
| Armistice Capital, LLC | 1,972,000 | $39.9M | 1.04% | +300,000+17.9% | Added |
| FCPM III Services B.V. | 2,122,892 | $43.0M | 6.34% | +2,122,892 | New |
| Ra Capital Management, L.P. | 2,253,000 | $45.6M | 0.60% | +1,453,000+181.6% | Added |
| Deep Track Capital, LP | 3,490,506 | $70.6M | 2.11% | 00.0% | Unchanged |
| Baker Bros. Advisors LP | 9,399,960 | $190.3M | 2.43% | +4,457,137+90.2% | Added |
| Paradigm Biocapital Advisors LP | 0 | $0 | 0.00% | −3,246,759−100.0% | Sold out |
| Suvretta Capital Management, LLC | 0 | $0 | 0.00% | −914,476−100.0% | Sold out |
| Trexquant Investment LP | 0 | $0 | 0.00% | −92,552−100.0% | Sold out |
| Concurrent Investment Advisors, LLC | 0 | $0 | 0.00% | −21,799−100.0% | Sold out |
| ADAR1 Capital Management, LLC | 0 | $0 | 0.00% | −14,430−100.0% | Sold out |
| Danske Bank A/S | 0 | $0 | 0.00% | −13,330−100.0% | Sold out |
| Fishman Jay A Ltd | 0 | $0 | 0.00% | −9,000−100.0% | Sold out |
| PDS Planning, Inc | 0 | $0 | 0.00% | −8,450−100.0% | Sold out |
| Leonteq Securities AG | 0 | $0 | 0.00% | −5,000−100.0% | Sold out |
| First Manhattan Co | 0 | $0 | 0.00% | −2,200−100.0% | Sold out |
| US Bancorp | 0 | $0 | 0.00% | −300−100.0% | Sold out |
| Group One Trading, L.P. | 0 | $0 | 0.00% | −91−100.0% | Sold out |
| Northwestern Mutual Wealth Management Co | 0 | $0 | 0.00% | −5−100.0% | Sold out |
| Zurcher Kantonalbank (Zurich Cantonalbank) | 0 | $0 | 0.00% | −4−100.0% | Sold out |